DOCSLIB.ORG

Glial Cell Dysfunction in C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glial Cell Dysfunction in C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia cells Review Glial Cell Dysfunction in C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Mehdi Ghasemi * , Kiandokht Keyhanian and Catherine Douthwright Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01655, USA; [email protected] (K.K.); [email protected] (C.D.) * Correspondence: [email protected]; Tel.: +1-774-441-7726; Fax: +1-508-856-4485 Abstract: Since the discovery of the chromosome 9 open reading frame 72 (C9orf72) repeat expansion mutation in 2011 as the most common genetic abnormality in amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease) and frontotemporal dementia (FTD), progress in understanding the signaling pathways related to this mutation can only be described as intriguing. Two major theories have been suggested—(i) loss of function or haploinsufficiency and (ii) toxic gain of function from either C9orf72 repeat RNA or dipeptide repeat proteins (DPRs) generated from repeat-associated non-ATG (RAN) translation. Each theory has provided various signaling pathways that potentially participate in the disease progression. Dysregulation of the immune system, particularly glial cell dysfunction (mainly microglia and astrocytes), is demonstrated to play a pivotal role in both loss and gain of function theories of C9orf72 pathogenesis. In this review, we discuss the pathogenic roles of glial cells in C9orf72 ALS/FTD as evidenced by pre-clinical and clinical studies showing the presence of gliosis in C9orf72 ALS/FTD, pathologic hallmarks in glial cells, including TAR DNA-binding protein 43 (TDP-43) and p62 aggregates, and toxicity of C9orf72 glial cells. A better understanding of these pathways can provide new insights into the development of therapies targeting glial cell Citation: Ghasemi, M.; Keyhanian, abnormalities in C9orf72 ALS/FTD. K.; Douthwright, C. Glial Cell Dysfunction in C9orf72-Related Keywords: C9orf72 gene; C9orf72 repeat expansion mutation; amyotrophic lateral sclerosis (ALS); Amyotrophic Lateral Sclerosis and frontotemporal dementia (FTD); astrocytes; microglia; glial cells Frontotemporal Dementia. Cells 2021, 10, 249. https://doi.org/10.3390/ cells10020249 Academic Editors: Kyoungho Suk, 1. Introduction Makoto Tsuda and Hoon Ryu Amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease) and fron- Received: 30 December 2020 totemporal dementia (FTD) are two devastating neurodegenerative diseases with a high Accepted: 25 January 2021 burden on society. It is currently believed that ALS and FTD are parts of a disease spec- Published: 28 January 2021 trum that share clinical, genetic, and pathological findings. Clinically, 30–50% of ALS patients have cognitive deficits, and ~15% of patients with FTD exhibit symptoms/signs Publisher’s Note: MDPI stays neutral of ALS [1,2]. Histopathological studies have also shown that >97% of ALS and ~50% of with regard to jurisdictional claims in FTD patients aggregate inclusions of the TAR DNA-binding protein 43 (TDP-43) in both published maps and institutional affil- affected neurons and glial cells [3–7]. In 2011, a trio of teams [8–10] discovered a GGGGCC iations. (G4C2) nucleotide repeat expansion mutation in the first intron of the chromosome 9 open reading frame 72 (C9orf72) gene as the most frequent genetic cause in up to 35–45% of familial ALS, 5–20% of sporadic ALS, 15–25% of familial FTD, and 6–7% of sporadic FTD patients [11]. Although the number of hexanucleotide repeats varies considerably among Copyright: © 2021 by the authors. these patients, overall, repeat numbers of <30 are considered to be non-pathogenic [12]. Licensee MDPI, Basel, Switzerland. The relationship between repeat expansion size and phenotype is still equivocal, which This article is an open access article could be due to somatic variability in expansion size [2]. C9orf72 ALS patients have a mean distributed under the terms and onset age of 57 years old and a median survival rate of 30–37 months [13]. Although more conditions of the Creative Commons frequent bulbar onset has been reported in C9orf72 ALS patients compared to ALS patients Attribution (CC BY) license (https:// without a C9orf72 repeat expansion mutation [14–16], this is still debatable, because a creativecommons.org/licenses/by/ recent multi-center prospective natural history study on C9orf72 ALS cases reported a 4.0/). Cells 2021, 10, 249. https://doi.org/10.3390/cells10020249 https://www.mdpi.com/journal/cells Cells 2021, 10, x FOR PEER REVIEW 2 of 26 Cells 2021, 10, 249 2 of 25 a recent multi-center prospective natural history study on C9orf72 ALS cases reported a higher rate of limb (54%) than bulbar (39%) onset [13]. What is undebatable, however, is higher rate of limb (54%) than bulbar (39%) onset [13]. What is undebatable, however, is thatthat the the prevalence prevalence of of FTD is significantly significantly higher in C9orf72 ALS cases, accompanied by higherhigher rates of disease progression andand prominentprominent cognitive/behavioralcognitive/behavioral changes [14,17] [14,17] (Figure(Figure 11).). Co-morbidCo-morbid dementiadementia isis presentpresent inin 50%50% ofof C9orf72 ALS patients [[14].14]. C9orf72 FTDFTD patients havehave alsoalso more more common common psychotic psychotic features features and and irrational irrational behavior behavior compared com- paredto non- toC9orf72 non-C9orf72FTD cases FTD [cases18,19 ].[18,19]. FigureFigure 1. Clinical 1. Clinical findings findings at onset at onsetin the inchromosome the chromosome 9 open 9 reading open reading frame frame72 (C9orf72 72 (C9orf72)-associated)-associated amyotrophic amyotrophic lateral lateralsclerosis (ALS)/frontotemporalsclerosis (ALS)/frontotemporal dementia (FTD). dementia (FTD). AlthoughAlthough muchmuch moremore research research is neededis needed to understand to understand the normal the normal function function of C9orf72 of C9orf72in humans, in humans, the discovery the discovery of C9orf72 of C9orf72repeat repeat expansion expansion mutations mutations as the as mostthe most common com- mongenetic genetic etiology etiology in ALS/FTD in ALS/FTD has openedhas opened a new a new avenue avenue of research of research for elucidatingfor elucidating dis- diseaseease mechanisms mechanisms and, and, ultimately, ultimately, therapeutic therapeutic approaches approaches for for this this fatal fatal disease.disease. Initial observationsobservations identifiedidentified decreaseddecreased levelslevels of of C9orf72 C9orf72 protein protein in in several several brain/spinal brain/spinal cord cord re- gions [8,10,20–25], suggesting a loss of function or haploinsufficiency as a main pathogenic regions [8,10,20–25], suggesting a loss of function or haploinsufficiency as a main patho- mechanism. Using a variety of C9orf72 knock out/down animal models, several mech- genic mechanism. Using a variety of C9orf72 knock out/down animal models, several anisms related to this theory were suggested, including aberrant autophagy, disrupted mechanisms related to this theory were suggested, including aberrant autophagy, dis- endosomal/lysosomal or endoplasmic reticulum (ER)-Golgi transport systems, and excito- rupted endosomal/lysosomal or endoplasmic reticulum (ER)-Golgi transport systems, toxicity [2,26]. Although this hypothesis still explains several aspects of C9orf72 ALS/FTD and excitotoxicity [2,26]. Although this hypothesis still explains several aspects of C9orf72 pathogenesis, other investigators have proposed a gain of toxic function, through the ALS/FTD pathogenesis, other investigators have proposed a gain of toxic function, generation of toxic RNA repeats and dipeptide repeat proteins (DPRs) [2]. In recent years, through the generation of toxic RNA repeats and dipeptide repeat proteins (DPRs) [2]. In compelling evidence indicates a role for immune dysregulation, particularly related to glial recent years, compelling evidence indicates a role for immune dysregulation, particularly cell abnormalities, as an important mechanism underlying C9orf72 ALS/FTD pathogenesis. related to glial cell abnormalities, as an important mechanism underlying C9orf72 Here, we comprehensively review the current literature on the pathogenic roles of glial cells, ALS/FTD pathogenesis. Here, we comprehensively review the current literature on the focusing on microglia and astrocytes, in C9orf72 ALS/FTD as evidenced by pre-clinical and pathogenicclinical studies. roles of glial cells, focusing on microglia and astrocytes, in C9orf72 ALS/FTD as evidenced by pre-clinical and clinical studies. 2. Overview of Pathogenic Mechanisms Underlying C9orf72 Repeat Expansion 2.Mutation Overview in of ALS/FTD Pathogenic Mechanisms Underlying C9orf72 Repeat Expansion Muta- tion2.1. Lossin ALS/FTD of Function Mechanisms 2.1. LossThe ofC9orf72 Functiongene Mechanisms consists of 11 exons (including two alternate non-coding first exons— 1a andThe 1b) C9orf72 [8]. Through gene consists alternative of 11 exons splicing, (includi it canng be two transcribed alternate intonon-coding three transcript first ex- ons—1avariants and (Figure 1b) 2[8].). TheThrough (G 4C alternative2)n repeat splicin expansiong, it mutationcan be transcribed is located into in intronthree tran- 1 of scriptvariants variants 1 and (Figure 3, whereas 2). The in variant (G4C2)n 2, repeat it is located expansion within mutation the promoter is located region in intron(Figure 1 2of). variantsTherefore, 1 and the 3, repeat whereas expansions in variant are 2, it not is located
Load more

Recommended publications
  • Magnetic Resonance Imaging of Multiple Sclerosis: a Study of Pulse-Technique Efficacy
    691 Magnetic Resonance Imaging of Multiple Sclerosis: A Study of Pulse-Technique Efficacy Val M. Runge1 Forty-two patients with the clinical diagnosis of multiple sclerosis were examined by Ann C. Price1 proton magnetic resonance imaging (MRI) at 0.5 T. An extensive protocol was used to Howard S. Kirshner2 facilitate a comparison of the efficacy of different pulse techniques. Results were also Joseph H. Allen 1 compared in 39 cases with high-resolution x-ray computed tomography (CT). MRI revealed characteristic abnormalities in each case, whereas CT was positive in only 15 C. Leon Partain 1 of 33 patients. Milder grades 1 and 2 disease were usually undetected by CT, and in all A. Everette James, Jr.1 cases, the abnormalities noted on MRI were much more extensive than on CT. Cerebral abnormalities were best shown with the T2-weighted spin-echo sequence (TE/TR = 120/1000); brainstem lesions were best defined on the inversion-recovery sequence (TE/TI/TR =30/400/1250). Increasing TE to 120 msec and TR to 2000 msec heightened the contrast between normal and abnormal white matter. However, the signal intensity of cerebrospinal fluid with this pulse technique obscured some abnormalities. The diagnosis of multiple sclerosis continues to be a clinical challenge [1,2). The lack of an objective means of assessment further complicates the evaluation of treatment regimens. Evoked potentials, cerebrospinal fluid (CSF) analysis , and computed tomography (CT) are currently used for diagnosis, but all lack sensitivity and/or specificity. Furthermore, postmortem examinations demonstrate many more lesions than those suggested by clinical means [3).
    [Show full text]
  • The Reticulons: a Family of Proteins with Diverse Functions Yvonne S Yang and Stephen M Strittmatter
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central Protein family review The reticulons: a family of proteins with diverse functions Yvonne S Yang and Stephen M Strittmatter Address: Program in Cellular Neuroscience, Neurodegeneration and Repair, Department of Neurology, Yale University School of Medicine, New Haven, CT 06536, USA. Correspondence: Stephen M Strittmatter. Email: [email protected] Published: 28 December 2007 Genome Biology 2007, 8:234 (doi:10.1186/gb-2007-8-12-234) The electronic version of this article is the complete one and can be found online at http://genomebiology.com/2007/8/12/234 © 2007 BioMed Central Ltd Summary The reticulon family is a large and diverse group of membrane-associated proteins found throughout the eukaryotic kingdom. All of its members contain a carboxy-terminal reticulon homology domain that consists of two hydrophobic regions flanking a hydrophilic loop of 60-70 amino acids, but reticulon amino-terminal domains display little or no similarity to each other. Reticulons principally localize to the endoplasmic reticulum, and there is evidence that they influence endoplasmic reticulum-Golgi trafficking, vesicle formation and membrane morphogenesis. However, mammalian reticulons have also been found on the cell surface and mammalian reticulon 4 expressed on the surface of oligodendrocytes is an inhibitor of axon growth both in culture and in vivo. There is also growing evidence that reticulons may be important in neurodegenerative diseases such as Alzheimer’s disease and amyotrophic lateral sclerosis. The diversity of structure, topology, localization and expression patterns of reticulons is reflected in their multiple, diverse functions in the cell.
    [Show full text]
  • Functions of Nogo Proteins and Their Receptors in the Nervous System
    REVIEWS Functions of Nogo proteins and their receptors in the nervous system Martin E. Schwab Abstract | The membrane protein Nogo-A was initially characterized as a CNS-specific inhibitor of axonal regeneration. Recent studies have uncovered regulatory roles of Nogo proteins and their receptors — in precursor migration, neurite growth and branching in the developing nervous system — as well as a growth-restricting function during CNS maturation. The function of Nogo in the adult CNS is now understood to be that of a negative regulator of neuronal growth, leading to stabilization of the CNS wiring at the expense of extensive plastic rearrangements and regeneration after injury. In addition, Nogo proteins interact with various intracellular components and may have roles in the regulation of endoplasmic reticulum (ER) structure, processing of amyloid precursor protein and cell survival. Nogo proteins were discovered, and have been exten- The amino-terminal segments of the proteins sively studied, in the context of injury and repair of fibre encoded by the different RTN genes have differing tracts in the CNS1 — a topic of great research interest lengths and there is no homology between them3,5. The and clinical relevance. However, much less in known N termini of the RTN4 products Nogo-A and Nogo-B are about the physiological functions of Nogo proteins in identical, consisting of a 172-amino acid sequence that development and in the intact adult organism, including is encoded by a single exon (exon 1) that is followed by in the brain. Through a number of recent publications, a short exon 2 and, in Nogo-A, by the very long exon Nogo proteins have emerged as important regulators of 3 encoding 800 amino acids2,6 (FIG.
    [Show full text]
  • Structural Studies of C9orf72-SMCR8-WDR41 Protein Complex
    Structural Studies of C9orf72-SMCR8-WDR41 Protein Complex Valeria Shkuratova Department of Biochemistry McGill University, Montreal A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Master of Science © Valeria Shkuratova, 2020 Table of Contents Abstract ............................................................................................................................................ 3 Résumé ............................................................................................................................................ 4 Acknowledgment ............................................................................................................................. 5 Author Contribution ........................................................................................................................ 6 List of Abbreviations ....................................................................................................................... 7 List of Figures .................................................................................................................................. 9 List of Tables ................................................................................................................................... 9 Introduction ................................................................................................................................... 10 1. Amyotrophic Lateral Sclerosis (ALS) ..............................................................................
    [Show full text]
  • The Proline/Arginine Dipeptide from Hexanucleotide Repeat Expanded C9ORF72 Inhibits the Proteasome
    New Research Disorders of the Nervous System The Proline/Arginine Dipeptide from Hexanucleotide Repeat Expanded C9ORF72 Inhibits the Proteasome Jelena Mojsilovic-Petrovic,4 Won Hoon Choi,5 Nathaniel Safren,6 ء,Matthews Lan,3 ء,Rahul Gupta,1,2 Sami Barmada,6 Min Jae Lee,5 and Robert Kalb4,7 DOI:http://dx.doi.org/10.1523/ENEURO.0249-16.2017 1Department of Chemical and Biomolecular Engineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, PA, 19104, 2Department of Biology, College of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, 19104, 3Department of Biochemistry, College of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, 19104, 4Division of Neurology, Department of Pediatrics, Research Institute, Children’s Hospital of Philadelphia, Philadelphia, PA, 19104, 5Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea, 6Department of Neurology, University of Michigan, Ann Arbor, MI, 48109, and 7Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104 Abstract An intronic hexanucleotide repeat expansion (HRE) mutation in the C9ORF72 gene is the most common cause of familial ALS and frontotemporal dementia (FTD) and is found in ϳ7% of individuals with apparently sporadic disease. Several different diamino acid peptides can be generated from the HRE by noncanonical translation (repeat-associated non-ATG translation, or RAN translation), and some of these peptides can be toxic. Here, we studied the effects of two arginine containing RAN translation products [proline/arginine repeated 20 times (PR20) and glycine/arginine repeated 20 times (GR20)] in primary rat spinal cord neuron cultures grown on an astrocyte ␮ feeder layer.
    [Show full text]
  • C9orf72 Testing in a Diagnostic Laboratory Using the Asuragen Amplidex® PCR/CE C9orf72 Kit
    C9orf72 testing in a diagnostic laboratory using the Asuragen AmplideX® PCR/CE C9orf72 kit Rick van Minkelen1, Patricia Reichgelt1, Saskia Theunisse2, Jody Salomon2, Kristen Culp3, Dept. Clinical Genetics Janne M. Papma4, Laura Donker Kaat4,5, John C. van Swieten4,6, Raoul van de Graaf1, Lies H. Hoefsloot1, Martina Wilke1 1 Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands 2 Sanbio B.V., Uden, the Netherlands 3 Asuragen, Inc., Austin, TX, USA 4 Department of Neurology, Erasmus MC, Rotterdam, the Netherlands 5 Department of Clinical Genetics, LUMC, Leiden, the Netherlands 6 Department of Clinical Genetics, VUMC, Amsterdam, the Netherlands [email protected] Introduction The pathogenic expanded hexanucleotide repeat element (G4C2) in intron 1 of the Chromosome 9 open reading frame 72 gene (C9orf72; Results NM_001256054.2) is the most prevalent genetic cause of the All samples previously scored as pathogenic using the home-made tests neurodegenerative disorders frontotemporal dementia (FTD) and also showed a pathogenic repeat expansion of at least 145 repeats using amyotrophic lateral sclerosis (ALS). Here we describe our experiences in the new Asuragen test (for examples see Figure 1). No repeats were sized using the newly introduced Asuragen AmplideX® PCR/CE C9orf72 assay in the range 60-145. Repeats in the normal range were sized exactly the compared to our home-made long range and repeat-primed PCR tests for same. DNA concentrations of 50ng/µl (our standard lab dilution) and the detection of C9orf72 repeats. Our home-made tests are limited to 25ng/µl showed similar results. A dilution (including a second 30s injection detection of up to ~60 C9orf72 repeats.
    [Show full text]
  • Genetic Testing and Genetic Counseling for Amyotrophic Lateral Sclerosis: an Update for Clinicians
    © American College of Medical Genetics and Genomics REVIEW Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians Jennifer Roggenbuck, MS1, Adam Quick, MD1 and Stephen J. Kolb, MD, PhD1 Patients with amyotrophic lateral sclerosis (ALS) often have questions SOD1 antisense oligonucleotide trials. In the span of a few years, ALS about why they developed the disease and the likelihood that family genetic testing options have progressed from testing of a single gene members will also be affected. In recent years, providing answers to to multigene next-generation sequencing panels and whole-exome these questions has become more complex with the identification of sequencing. This article provides suggestions for genetic counseling multiple novel genes, the newly recognized etiologic link between ALS and genetic testing for ALS in this new environment. and frontotemporal dementia (FTD), and the increased availability of Genet Med advance online publication 18 August 2016 commercial genetic testing. A genetic diagnosis is particularly impor- tant to establish in the era of emerging gene-based therapies, such as Key Words: motor neuron disease; C9orf72 INTRODUCTION of novel genes, including C9orf72, the recognition of the link Amyotrophic lateral sclerosis (ALS) is an adult-onset neuro- between ALS and frontotemporal dementia (FTD), and the advent degenerative disorder characterized by loss of upper and lower of next-generation sequencing technology. The genetic basis of motor neurons, progressive paralysis, and death within an aver- two-thirds of fALS and 10% of sALS case has now been estab- age of 2–5 years after symptom onset. Diagnosis is based on lished.
    [Show full text]
  • Electrophysiological Changes That Accompany Reactive Gliosis in Vitro
    The Journal of Neuroscience, October 1, 1997, 17(19):7316–7329 Electrophysiological Changes That Accompany Reactive Gliosis In Vitro Stacey Nee MacFarlane and Harald Sontheimer Department of Neurobiology, University of Alabama, Birmingham, Birmingham, Alabama 35294 An in vitro injury model was used to examine the electrophys- negative resting potentials in nonproliferating (260 mV) versus iological changes that accompany reactive gliosis. Mechanical proliferating astrocytes (253 mV; p 5 0.015). Although 45% of scarring of confluent spinal cord astrocytes led to a threefold the nonproliferating astrocytes expressed Na 1 currents (0.47 increase in the proliferation of scar-associated astrocytes, as pS/pF), the majority of proliferating cells expressed prominent judged by bromodeoxyuridine (BrdU) labeling. Whole-cell Na 1 currents (0.94 pS/pF). Injury-induced electrophysiological patch-clamp recordings demonstrated that current profiles dif- changes are rapid and transient, appearing within 4 hr postin- 2 fered absolutely between nonproliferating (BrdU ) and prolifer- jury and, with the exception of KIR , returning to control con- ating (BrdU 1) astrocytes. The predominant current type ex- ductances within 24 hr. These differences between proliferating pressed in BrdU 2 cells was an inwardly rectifying K 1 current and nonproliferating astrocytes are reminiscent of electrophys- 2 (KIR ; 1.3 pS/pF). BrdU cells also expressed transient outward iological changes observed during gliogenesis, suggesting that K 1 currents, accounting for less than
    [Show full text]
  • A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9P21-Linked ALS- FTD, Neuron (2011), Doi:10.1016/J.Neuron.2011.09.010 Neuron Article
    Please cite this article in press as: Renton et al., A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS- FTD, Neuron (2011), doi:10.1016/j.neuron.2011.09.010 Neuron Article AHexanucleotideRepeatExpansioninC9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD Alan E. Renton,1,38 Elisa Majounie,2,38 Adrian Waite,3,38 Javier Simo´ n-Sa´ nchez,4,5,38 Sara Rollinson,6,38 J. Raphael Gibbs,7,8,38 Jennifer C. Schymick,1,38 Hannu Laaksovirta,9,38 John C. van Swieten,4,5,38 Liisa Myllykangas,10 Hannu Kalimo,10 Anders Paetau,10 Yevgeniya Abramzon,1 Anne M. Remes,11 Alice Kaganovich,12 Sonja W. Scholz,2,13,14 Jamie Duckworth,7 Jinhui Ding,7 Daniel W. Harmer,15 Dena G. Hernandez,2,8 Janel O. Johnson,1,8 Kin Mok,8 Mina Ryten,8 Danyah Trabzuni,8 Rita J. Guerreiro,8 Richard W. Orrell,16 James Neal,17 Alex Murray,18 Justin Pearson,3 Iris E. Jansen,4 David Sondervan,4 Harro Seelaar,5 Derek Blake,3 Kate Young,6 Nicola Halliwell,6 Janis Bennion Callister,6 Greg Toulson,6 Anna Richardson,19 Alex Gerhard,19 Julie Snowden,19 David Mann,19 David Neary,19 Michael A. Nalls,2 Terhi Peuralinna,9 Lilja Jansson,9 Veli-Matti Isoviita,9 Anna-Lotta Kaivorinne,11 Maarit Ho¨ ltta¨ -Vuori,20 Elina Ikonen,20 Raimo Sulkava,21 Michael Benatar,22 Joanne Wuu,23 Adriano Chio` ,24 Gabriella Restagno,25 Giuseppe Borghero,26 Mario Sabatelli,27 The ITALSGEN Consortium,28 David Heckerman,29 Ekaterina Rogaeva,30 Lorne Zinman,31 Jeffrey D.
    [Show full text]
  • Application of Microrna Database Mining in Biomarker Discovery and Identification of Therapeutic Targets for Complex Disease
    Article Application of microRNA Database Mining in Biomarker Discovery and Identification of Therapeutic Targets for Complex Disease Jennifer L. Major, Rushita A. Bagchi * and Julie Pires da Silva * Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; [email protected] * Correspondence: [email protected] (R.A.B.); [email protected] (J.P.d.S.) Supplementary Tables Methods Protoc. 2021, 4, 5. https://doi.org/10.3390/mps4010005 www.mdpi.com/journal/mps Methods Protoc. 2021, 4, 5. https://doi.org/10.3390/mps4010005 2 of 25 Table 1. List of all hsa-miRs identified by Human microRNA Disease Database (HMDD; v3.2) analysis. hsa-miRs were identified using the term “genetics” and “circulating” as input in HMDD. Targets CAD hsa-miR-1 Targets IR injury hsa-miR-423 Targets Obesity hsa-miR-499 hsa-miR-146a Circulating Obesity Genetics CAD hsa-miR-423 hsa-miR-146a Circulating CAD hsa-miR-149 hsa-miR-499 Circulating IR Injury hsa-miR-146a Circulating Obesity hsa-miR-122 Genetics Stroke Circulating CAD hsa-miR-122 Circulating Stroke hsa-miR-122 Genetics Obesity Circulating Stroke hsa-miR-26b hsa-miR-17 hsa-miR-223 Targets CAD hsa-miR-340 hsa-miR-34a hsa-miR-92a hsa-miR-126 Circulating Obesity Targets IR injury hsa-miR-21 hsa-miR-423 hsa-miR-126 hsa-miR-143 Targets Obesity hsa-miR-21 hsa-miR-223 hsa-miR-34a hsa-miR-17 Targets CAD hsa-miR-223 hsa-miR-92a hsa-miR-126 Targets IR injury hsa-miR-155 hsa-miR-21 Circulating CAD hsa-miR-126 hsa-miR-145 hsa-miR-21 Targets Obesity hsa-mir-223 hsa-mir-499 hsa-mir-574 Targets IR injury hsa-mir-21 Circulating IR injury Targets Obesity hsa-mir-21 Targets CAD hsa-mir-22 hsa-mir-133a Targets IR injury hsa-mir-155 hsa-mir-21 Circulating Stroke hsa-mir-145 hsa-mir-146b Targets Obesity hsa-mir-21 hsa-mir-29b Methods Protoc.
    [Show full text]
  • Disrupted Neuronal Trafficking in Amyotrophic Lateral Sclerosis
    Acta Neuropathologica (2019) 137:859–877 https://doi.org/10.1007/s00401-019-01964-7 REVIEW Disrupted neuronal trafcking in amyotrophic lateral sclerosis Katja Burk1,2 · R. Jeroen Pasterkamp3 Received: 12 October 2018 / Revised: 19 January 2019 / Accepted: 19 January 2019 / Published online: 5 February 2019 © The Author(s) 2019 Abstract Amyotrophic lateral sclerosis (ALS) is a progressive, adult-onset neurodegenerative disease caused by degeneration of motor neurons in the brain and spinal cord leading to muscle weakness. Median survival after symptom onset in patients is 3–5 years and no efective therapies are available to treat or cure ALS. Therefore, further insight is needed into the molecular and cellular mechanisms that cause motor neuron degeneration and ALS. Diferent ALS disease mechanisms have been identi- fed and recent evidence supports a prominent role for defects in intracellular transport. Several diferent ALS-causing gene mutations (e.g., in FUS, TDP-43, or C9ORF72) have been linked to defects in neuronal trafcking and a picture is emerging on how these defects may trigger disease. This review summarizes and discusses these recent fndings. An overview of how endosomal and receptor trafcking are afected in ALS is followed by a description on dysregulated autophagy and ER/ Golgi trafcking. Finally, changes in axonal transport and nucleocytoplasmic transport are discussed. Further insight into intracellular trafcking defects in ALS will deepen our understanding of ALS pathogenesis and will provide novel avenues for therapeutic intervention. Keywords Amyotrophic lateral sclerosis · Motor neuron · Trafcking · Cytoskeleton · Rab Introduction onset is about 10 years earlier [44]. As disease progresses, corticospinal motor neurons, projecting from the motor cor- Amyotrophic lateral sclerosis (ALS) is a fatal disease char- tex to the brainstem and spinal cord, and bulbar and spinal acterized by the degeneration of upper and lower motor motor neurons, projecting to skeletal muscles, degenerate.
    [Show full text]
  • Cell Biology of Spinal Cord Injury and Repair
    The Journal of Clinical Investigation REVIEW SERIES: GLIA AND NEURODEGENERATION Series Editors: Marco Colonna and David Holtzmann Cell biology of spinal cord injury and repair Timothy M. O’Shea, Joshua E. Burda, and Michael V. Sofroniew Department of Neurobiology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA. Spinal cord injury (SCI) lesions present diverse challenges for repair strategies. Anatomically complete injuries require restoration of neural connectivity across lesions. Anatomically incomplete injuries may benefit from augmentation of spontaneous circuit reorganization. Here, we review SCI cell biology, which varies considerably across three different lesion- related tissue compartments: (a) non-neural lesion core, (b) astrocyte scar border, and (c) surrounding spared but reactive neural tissue. After SCI, axon growth and circuit reorganization are determined by neuron-cell-autonomous mechanisms and by interactions among neurons, glia, and immune and other cells. These interactions are shaped by both the presence and the absence of growth-modulating molecules, which vary markedly in different lesion compartments. The emerging understanding of how SCI cell biology differs across lesion compartments is fundamental to developing rationally targeted repair strategies. Introduction a central non-neural lesion core, often referred to as fibrotic scar Spinal cord injury (SCI) is a major cause of long-term physical (also mesenchymal or connective tissue scar); (b) an astroglial impairment. Current treatments are limited mostly to supportive scar border that intimately surrounds the lesion core; and (c) a sur- measures. Affected individuals often have life expectancies of rounding zone of viable neural tissue that is spared and function- decades with permanent disability (1–3).
    [Show full text]